Revium Rx.

Revium Rx is a pre-clinical stage biopharmaceutical company that develops proprietary nanoparticle-based therapies to treat life-threatening conditions. The company utilizes advanced lipid-based delivery platforms to encapsulate therapeutic compounds, with the goal of increasing drug efficacy while minimizing systemic toxicity. Its research pipeline concentrates on severe infections, solid tumors, and novel immunization methods. Core product candidates include Nano-Mupirocin, a systemically administered formulation aimed at multi-drug resistant bacterial infections, and Nano-Candesartan, an intravenous adjunct therapy targeting pancreatic cancer. Additionally, the company is researching liposomal protein-loaded technology for vaccine delivery. Its target recipients are patients suffering from severe diseases with limited therapeutic options.

The company operates primarily through its Israeli subsidiary, LipoVation Ltd. Its laboratory evaluations and formulation processes have demonstrated capability to produce up to five-liter batches, with potential scaling to twenty-five liters. Revium Rx maintains its principal executive offices in Herzliya, Israel, while being incorporated under the laws of the State of Nevada.

Summary of the business section of Revium Rx.'s latest annual report, written by StockData.